Retinoid x receptor heterodimers in the metabolic syndrome.
Shulman
Andrew I
AI
Howard Hughes Medical Institute, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas 75390, USA.
Mangelsdorf
David J
DJ
D000818:Animals; D004268:DNA-Binding Proteins / Q000819:agonists* / Q000378:metabolism; D019281:Dimerization; D006801:Humans; D000071518:Liver X Receptors; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000378:metabolism; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism; D011487:Protein Conformation; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000378:metabolism; D011988:Receptors, Thyroid Hormone / Q000819:agonists / Q000378:metabolism; D047488:Retinoid X Receptors / Q000819:agonists* / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D015398:Signal Transduction; D014157:Transcription Factors / Q000819:agonists / Q000378:metabolism; D000099150:Receptor, Farnesoid X-Activated
D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D011988:Receptors, Thyroid Hormone; D047488:Retinoid X Receptors; D014157:Transcription Factors; D000099150:Receptor, Farnesoid X-Activated